Yoichi Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoichi Nakamura has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hironori Sagara
Showa Medical University 6 Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine Tokyo, Japan
2 shared publications - Noboru Takeichi
東京都立大学大学院システムデザイン研究科航空宇宙システム工学
2 shared publications Abhijit Pethe
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
1 shared publication- Ana-Maria Tanase
Novartis Pharma AG, Basel, Switzerland
1 shared publication - Andrew Fowler
GlaxoSmithKline plc., Middlesex TW8 9GS, UK
1 shared publication Atsushi Isozaki
Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan
1 shared publication
Latest Publications
- 30 May 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (2) , 403-411
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies
The 52-week long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) high-dose (150/50/160 µg) and IND/MF high-dose (150/320 µg) was evaluated in two studies enrolling Japanese patients with inadequately controlled asthma. Study 1 (IND/GLY/MF) and Study 2 (IND/MF) were 52-week, phase III, open-label, single-arm, multicenter studies conducted in Japanese adult patients with inadequately controlled asthma. The primary endpoint was incidence and severity of treatment-emergent adverse events (AEs) over 52-weeks. In Study 1, 94 patients received IND/GLY/MF high-dose and 84 (89.4%) patients completed the 52-week study treatment; in Study 2, 51 patients received IND/MF high-dose and 48 (94.1%) patients completed the 52-week study treatment. In Study 1, 68.1% and 6.4% of 94 patients reported ≥1 AE and ≥1 serious AE (SAE) respectively. In Study 2, 78.4% of 51 patients reported ≥1 AE; no patients reported SAEs. The most commonly reported AEs were asthma (exacerbation; 30.9% and 54.9%) and nasopharyngitis (18.1% and 29.4%) in Study 1 and Study 2, respectively. Severe AEs including asthma (exacerbation) were reported in 13.8% and 13.7% of patients in Study 1 and Study 2, respectively. In Study 1, 10 patients (10.6%) reported treatment-related AEs, of which dysphonia (9 patients [9.6%]) was the most commonly reported; no treatment-related AEs were reported in Study 2. In Study 1, one death (not study drug-related) was reported after study discontinuation (92 days after last dose of study medication). Once-daily IND/GLY/MF and IND/MF high-dose were well-tolerated in Japanese patients with inadequately controlled asthma. No unexpected safety findings were observed. Supplemental data for this article is available online at
- 30 May 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (2) , 403-411
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies
The 52-week long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) high-dose (150/50/160 µg) and IND/MF high-dose (150/320 µg) was evaluated in two studies enrolling Japanese patients with inadequately controlled asthma. Study 1 (IND/GLY/MF) and Study 2 (IND/MF) were 52-week, phase III, open-label, single-arm, multicenter studies conducted in Japanese adult patients with inadequately controlled asthma. The primary endpoint was incidence and severity of treatment-emergent adverse events (AEs) over 52-weeks. In Study 1, 94 patients received IND/GLY/MF high-dose and 84 (89.4%) patients completed the 52-week study treatment; in Study 2, 51 patients received IND/MF high-dose and 48 (94.1%) patients completed the 52-week study treatment. In Study 1, 68.1% and 6.4% of 94 patients reported ≥1 AE and ≥1 serious AE (SAE) respectively. In Study 2, 78.4% of 51 patients reported ≥1 AE; no patients reported SAEs. The most commonly reported AEs were asthma (exacerbation; 30.9% and 54.9%) and nasopharyngitis (18.1% and 29.4%) in Study 1 and Study 2, respectively. Severe AEs including asthma (exacerbation) were reported in 13.8% and 13.7% of patients in Study 1 and Study 2, respectively. In Study 1, 10 patients (10.6%) reported treatment-related AEs, of which dysphonia (9 patients [9.6%]) was the most commonly reported; no treatment-related AEs were reported in Study 2. In Study 1, one death (not study drug-related) was reported after study discontinuation (92 days after last dose of study medication). Once-daily IND/GLY/MF and IND/MF high-dose were well-tolerated in Japanese patients with inadequately controlled asthma. No unexpected safety findings were observed. Supplemental data for this article is available online at
- Open Access
- 14 July 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (9) , 1657-1665
Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
In CAPTAIN a double-blind, parallel-group, Phase IIIA study, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) improved lung function, symptoms and asthma control versus FF/VI in patients wi...
- 14 July 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (9) , 1657-1665
Open AccessEfficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
In CAPTAIN a double-blind, parallel-group, Phase IIIA study, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) improved lung function, symptoms and asthma control versus FF/VI in patients wi...
- Open Access
- 1 October 2015
- Published by Elsevier in Allergology International
- Vol. 64 (4) , 359-363
Elevated exhaled nitric oxide in anaphylaxis with respiratory symptoms
- 1 October 2015
- Published by Elsevier in Allergology International
- Vol. 64 (4) , 359-363
Open AccessElevated exhaled nitric oxide in anaphylaxis with respiratory symptoms
- Open Access
- 1 January 2012
- Published by Japan Society for Aeronautical and Space Sciences in JOURNAL OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES
- Vol. 60 (1) , 17-23
Decentralized Control of an Unidirectional Air Traffic Flow with Flight Speed Distribution
- 1 January 2012
- Published by Japan Society for Aeronautical and Space Sciences in JOURNAL OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES
- Vol. 60 (1) , 17-23
Open AccessDecentralized Control of an Unidirectional Air Traffic Flow with Flight Speed Distribution
- Open Access
- 1 January 2009
- Published by Japan Society of Mechanical Engineers in TRANSACTIONS OF THE JAPAN SOCIETY OF MECHANICAL ENGINEERS Series B
- Vol. 75 (749) , 110-116
Dynamic Characteristics and Stability of a Centrifugal Blood Pump with Hydrodynamic Levitation under Flow Fluctuation(Fluids Engineering)
- 1 January 2009
- Published by Japan Society of Mechanical Engineers in TRANSACTIONS OF THE JAPAN SOCIETY OF MECHANICAL ENGINEERS Series B
- Vol. 75 (749) , 110-116
Open AccessDynamic Characteristics and Stability of a Centrifugal Blood Pump with Hydrodynamic Levitation under Flow Fluctuation(Fluids Engineering)
- 6 November 2007
- Published by Wiley in Anatomia, Histologia, Embryologia
- Vol. 37 (2) , 126-130
Structure of Thymic Cysts in Congenital Lymph Nodes-lacking Mice
The ALY (aly/aly) mouse, a mutant of the C57BL/6j strain, has a severe immunodeficiency because of immature development of the immune organs. Both lymph nodes and Peyer’s patches are lacking and both the thymus and spleen are small. Previous microscopical observation of their thymus glands revealed the presence of an indistinct border between the cortex and medulla, the absence of Hassal’s corpuscles and the reduction of the medullary epithelial cell population. However, other microscopical findings for these glands have not yet been reported. In the present study, we performed light and electron microscopical observation of the thymus and found the consistent presence of extremely irregular shaped cystic cavities lined by microvilli‐bearing epithelium in the medulla. The cysts comprised ceca and did not open into adjacent capillaries, although they contained some lymphocytes and macrophages in their lumens. In the thymus glands of normal C57BL/6j mice, only some small cysts oval in shape could be inconspicuously found in the medulla. Therefore, the thymic cysts may normally regress during thymic development, however, in ALY mice, the cysts may remain because of the organ immaturity.
- 6 November 2007
- Published by Wiley in Anatomia, Histologia, Embryologia
- Vol. 37 (2) , 126-130
Structure of Thymic Cysts in Congenital Lymph Nodes-lacking Mice
The ALY (aly/aly) mouse, a mutant of the C57BL/6j strain, has a severe immunodeficiency because of immature development of the immune organs. Both lymph nodes and Peyer’s patches are lacking and both the thymus and spleen are small. Previous microscopical observation of their thymus glands revealed the presence of an indistinct border between the cortex and medulla, the absence of Hassal’s corpuscles and the reduction of the medullary epithelial cell population. However, other microscopical findings for these glands have not yet been reported. In the present study, we performed light and electron microscopical observation of the thymus and found the consistent presence of extremely irregular shaped cystic cavities lined by microvilli‐bearing epithelium in the medulla. The cysts comprised ceca and did not open into adjacent capillaries, although they contained some lymphocytes and macrophages in their lumens. In the thymus glands of normal C57BL/6j mice, only some small cysts oval in shape could be inconspicuously found in the medulla. Therefore, the thymic cysts may normally regress during thymic development, however, in ALY mice, the cysts may remain because of the organ immaturity.
- Open Access
- 2 May 2006
- Published by Wiley in ChemInform
- Vol. 37 (21)
Asymmetric Synthesis of a Diastereomer of the Structure Proposed for Amphidinolide A and the Determination of Its Absolute Configuration.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
- 2 May 2006
- Published by Wiley in ChemInform
- Vol. 37 (21)
Open AccessAsymmetric Synthesis of a Diastereomer of the Structure Proposed for Amphidinolide A and the Determination of Its Absolute Configuration.
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.